Scarica l'app Stockscreener
24.53
1.45%
0.35
Precedente Chiudi:
$24.18
Aprire:
$24.25
Volume 24 ore:
6.53M
Relative Volume:
1.22
Capitalizzazione di mercato:
$12.19B
Reddito:
$4.45B
Utile/perdita netta:
$205.00M
Rapporto P/E:
61.33
EPS:
0.4
Flusso di cassa netto:
$372.00M
1 W Prestazione:
+4.52%
1M Prestazione:
+9.07%
6M Prestazione:
+69.06%
1 anno Prestazione:
+104.25%
Intervallo 1D:
$24.00
$24.74
Intervallo di 1 settimana:
$23.28
$24.84
Portata 52W:
$8.02
$24.84
Elanco Animal Health Inc Stock (ELAN) Company Profile
Nome
Elanco Animal Health Inc
Settore
Telefono
877-352-6261
Indirizzo
450 ELANCO CIRCLE, INDIANAPOLIS
Confronta ELAN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
24.53 | 12.01B | 4.45B | 205.00M | 372.00M | 0.40 |
|
ZTS
Zoetis Inc
|
124.65 | 55.21B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.16 | 51.59B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.83 | 43.51B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.76 | 37.11B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
464.93 | 20.32B | 3.08B | 1.24B | 1.07B | 25.61 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-11-21 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2025-11-19 | Aggiornamento | Argus | Hold → Buy |
| 2025-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-07-17 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-06-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-12-09 | Iniziato | UBS | Buy |
| 2024-12-02 | Iniziato | Leerink Partners | Market Perform |
| 2024-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-01-05 | Aggiornamento | Stifel | Hold → Buy |
| 2023-12-19 | Iniziato | Jefferies | Buy |
| 2023-12-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-07 | Iniziato | Exane BNP Paribas | Outperform |
| 2023-04-20 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-08-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-07-21 | Downgrade | Goldman | Buy → Sell |
| 2022-07-12 | Iniziato | Piper Sandler | Neutral |
| 2021-11-18 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-28 | Downgrade | Stifel | Buy → Hold |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-06-15 | Aggiornamento | Cleveland Research | Underperform → Neutral |
| 2021-05-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2021-05-11 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2021-04-15 | Iniziato | Stifel | Buy |
| 2021-03-22 | Downgrade | Gabelli & Co | Buy → Hold |
| 2021-02-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-09 | Downgrade | Argus | Buy → Hold |
| 2020-11-09 | Downgrade | Barclays | Overweight → Underweight |
| 2020-08-20 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-08-13 | Ripresa | Credit Suisse | Neutral |
| 2020-08-04 | Ripresa | Goldman | Buy |
| 2020-07-27 | Downgrade | Cleveland Research | Neutral → Underperform |
| 2020-04-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-10 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-11-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-23 | Iniziato | Barclays | Overweight |
| 2019-08-26 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-08-15 | Aggiornamento | UBS | Sell → Neutral |
| 2019-05-23 | Iniziato | Guggenheim | Neutral |
| 2019-03-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-03-13 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-02-12 | Iniziato | William Blair | Mkt Perform |
| 2019-01-23 | Iniziato | UBS | Sell |
| 2019-01-15 | Iniziato | Argus | Buy |
| 2018-10-15 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Elanco Animal Health Inc Borsa (ELAN) Ultime notizie
Poultry Antibiotic Market Is Booming Worldwide 2026-2033 - openPR.com
The Glucosamine Supplements for Dogs Market, Global Forecast 2026-2032 | Innovation Drives Canine Glucosamine Supplement Market with New Chewable and Liquid Formats - GlobeNewswire Inc.
Veterinary Vaccines Market to Reach USD 236 Million by 2031 | CAGR - openPR.com
Anticoccidial Drugs Market to Reach USD 2.52 Billion by 2033 | - openPR.com
Institution Moves: What is the next catalyst for Elanco Animal Health IncorporatedJuly 2025 Sentiment & Capital Efficient Trading Techniques - baoquankhu1.vn
Nisa Investment Advisors LLC Lowers Stock Holdings in Elanco Animal Health Incorporated $ELAN - MarketBeat
Investor Mood: Can Elanco Animal Health Incorporated reach all time highs this yearTrade Exit Report & AI Optimized Trade Strategies - baoquankhu1.vn
Risk Hedge: Can Elanco Animal Health Incorporated ride the EV wave2025 Biggest Moves & Reliable Entry Point Alerts - baoquankhu1.vn
Elanco Animal Health stock hits 52-week high at 24.51 USD - Investing.com Canada
Oregon Public Employees Retirement Fund Invests $2.01 Million in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Incorporated $ELAN Shares Purchased by SG Americas Securities LLC - MarketBeat
Veterinary Oncology Market Is Going to BoomGrowth - openPR.com
Merger Talk: Why Elanco Animal Health Incorporated stock could outperform in 2025July 2025 Action & High Accuracy Buy Signal Tips - moha.gov.vn
Elanco CEO: Gaining Market Share Via 'Major' Innovations - marketscreener.com
Elanco Animal Health (NYSE:ELAN) Sets New 52-Week HighHere's Why - MarketBeat
Trend Recap: What is the PEG ratio of Elanco Animal Health IncorporatedBull Run & Long-Term Safe Investment Ideas - baoquankhu1.vn
Elanco Animal Health Inc Presents at J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Louisiana State Employees Retirement System Makes New Investment in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health: Innovation-Led Growth Model Plus Credible Deleveraging Path (ELAN) - Seeking Alpha
Will Elanco Animal Health Incorporated stock benefit from automation2025 Performance Recap & Reliable Breakout Forecasts - ulpravda.ru
Will Elanco Animal Health Incorporated (5EA) stock outperform value peers2025 Major Catalysts & Smart Investment Allocation Tips - ulpravda.ru
S P Trends: Will Elanco Animal Health Incorporated stock outperform energy sector in 2025Market Performance Report & Technical Analysis for Trade Confirmation - ulpravda.ru
Will Elanco Animal Health Incorporated stock outperform energy sector in 2025Market Movement Recap & Daily Profit Maximizing Tips - ulpravda.ru
Assessing Elanco Animal Health (ELAN) Valuation After Befrena Approval And Turnaround Progress - Yahoo Finance
Veterinary Pain Management Drugs Market to hit US$ 3.00 Billion - openPR.com
Elanco Animal Health (NYSE:ELAN) Hits New 1-Year HighHere's What Happened - MarketBeat
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN), IQVIA Holdings (IQV) and Ascendis Pharma (ASND) - The Globe and Mail
Elanco Animal Health stock hits 52-week high at 23.71 USD - Investing.com Canada
Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Finviz
Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference – Company Announcement - Financial Times
Elanco Animal Health (ELAN) Valuation Check After Recent Share Price Pullback - simplywall.st
On-Farm Veterinary Diagnostic Solutions Market Booming with - openPR.com
Dogs Vaccines Market Strong Growth: New Report Highlights - openPR.com
Elanco Animal Health (NYSE:ELAN) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat
Elanco Animal Health Inc (ELAT) Fundamental Analysis - Meyka
Breaking News - Today's Veterinary Business
ELAN SEC FilingsElanco Animal Health 10-K, 10-Q, 8-K Forms - Stock Titan
Elanco Receives USDA Approval for Befrena (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis - Finviz
Elanco (ELAN) Gains USDA Approval for Befrena Injections - GuruFocus
Elanco (ELAN) Gains USDA Approval for New Canine Dermatology Tre - GuruFocus
Elanco gains approval of Befrena for canine dermatitis - Seeking Alpha
Elanco receives USDA approval for canine dermatitis treatment By Investing.com - Investing.com Canada
Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis – Company AnnouncementFT.com - Financial Times
Voya Investment Management LLC Sells 2,335,093 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis - PR Newswire
Elanco (ELAN) CEO Jeffrey Simmons reports new deferred stock units - Stock Titan
Elanco (ELAN) EVP reports new deferred stock units award - Stock Titan
Targets Report: Will Elanco Animal Health Incorporated 5EA stock outperform value peers2025 EndofYear Setup & Free Low Drawdown Momentum Trade Ideas - moha.gov.vn
Elanco Animal Health (ELAN) Stock Analysis: A 10.62% Potential Upside Awaits Investors - DirectorsTalk Interviews
Yousif Capital Management LLC Boosts Stock Holdings in Elanco Animal Health Incorporated $ELAN - MarketBeat
EBITDA per share of Elanco Animal Health, Inc. – FWB:5EA - TradingView — Track All Markets
Elanco Animal Health Inc Azioni (ELAN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.72%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):